| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1006012617 |
| P356 | DOI | 10.1038/NATURE20564 |
| P932 | PMC publication ID | 5583716 |
| P698 | PubMed publication ID | 27819683 |
| P50 | author | Daved H. Fremont | Q16195537 |
| Michael S. Diamond | Q28051146 | ||
| Estefania Fernandez | Q28805084 | ||
| James E. Crowe, Jr. | Q37366747 | ||
| Gopal Sapparapu | Q47696401 | ||
| Julie M. Fox | Q55190881 | ||
| Indira U Mysorekar | Q60545922 | ||
| Bin Cao | Q64866569 | ||
| Robin Bombardi | Q94512389 | ||
| Benjamin J Doranz | Q98196924 | ||
| Nurgun Kose | Q115654145 | ||
| P2093 | author name string | Haiyan Zhao | |
| Edgar Davidson | |||
| Christopher A Nelson | |||
| Trevor Barnes | |||
| Aubrey L Bryan | |||
| P2860 | cites work | Probable non-vector-borne transmission of Zika virus, Colorado, USA | Q22240615 |
| Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007 | Q22241244 | ||
| Rapid spread of emerging Zika virus in the Pacific area | Q22242651 | ||
| Zika virus: a previously slow pandemic spreads rapidly through the Americas | Q22242663 | ||
| Zika Virus Infection during Pregnancy in Mice Causes Placental Damage and Fetal Demise | Q24050115 | ||
| IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis | Q24646236 | ||
| Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy | Q24701766 | ||
| Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus | Q24737245 | ||
| Zika virus-associated neurological disorders: a review | Q25115004 | ||
| Utility of a Dengue-Derived Monoclonal Antibody to Enhance Zika Infection In Vitro | Q25708158 | ||
| Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus | Q26247258 | ||
| Specificity, cross-reactivity and function of antibodies elicited by Zika virus infection | Q26252507 | ||
| Modeling Zika Virus Infection in Pregnancy | Q26252516 | ||
| Vaginal Exposure to Zika Virus during Pregnancy Leads to Fetal Brain Infection | Q26699951 | ||
| Zika virus — reigniting the TORCH | Q26742229 | ||
| A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes | Q26860116 | ||
| Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus | Q27335008 | ||
| Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus | Q27473186 | ||
| The Stoichiometry of Antibody-Mediated Neutralization and Enhancement of West Nile Virus Infection | Q27488224 | ||
| Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses | Q27679859 | ||
| Enzymatic assembly of DNA molecules up to several hundred kilobases | Q28241142 | ||
| H7N9 influenza virus neutralizing antibodies that possess few somatic mutations | Q30385356 | ||
| Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition | Q34261496 | ||
| Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. | Q34607919 | ||
| Genotypic Differences in Dengue Virus Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus Breathing | Q36245225 | ||
| FcRn in the yolk sac endoderm of mouse is required for IgG transport to fetus | Q37178738 | ||
| An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies | Q37559465 | ||
| An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies | Q39976828 | ||
| Structural Basis of Zika Virus-Specific Antibody Protection | Q40056291 | ||
| Oxidative refolding from inclusion bodies | Q42225909 | ||
| Fc receptor but not complement binding is important in antibody protection against HIV. | Q46545827 | ||
| IMGT/junctionanalysis: IMGT standardized analysis of the V-J and V-D-J junctions of the rearranged immunoglobulins (IG) and T cell receptors (TR) | Q84245404 | ||
| P433 | issue | 7633 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Zika virus | Q202864 |
| antibody | Q79460 | ||
| fetopathy | Q1409154 | ||
| maternal health | Q6786626 | ||
| Zika virus replication | Q59434296 | ||
| P1104 | number of pages | 5 | |
| P5008 | on focus list of Wikimedia project | WikiProject Zika Corpus | Q54439832 |
| P304 | page(s) | 443-447 | |
| P577 | publication date | 2016-11-07 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice | |
| P478 | volume | 540 |
| Q93017534 | A Chimeric Zika Virus between Viral Strains MR766 and BeH819015 Highlights a Role for E-glycan Loop in Antibody-mediated Virus Neutralization |
| Q58606057 | A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates |
| Q43047463 | A DNA Vaccine Protects Human Immune Cells against Zika Virus Infection in Humanized Mice |
| Q93101098 | A Gorilla Adenovirus-Based Vaccine against Zika Virus Induces Durable Immunity and Confers Protection in Pregnancy |
| Q59245616 | A Recombinant Subunit Based Zika Virus Vaccine Is Efficacious in Non-human Primates |
| Q54558504 | A Single Injection of Human Neutralizing Antibody Protects against Zika Virus Infection and Microcephaly in Developing Mouse Embryos. |
| Q90629672 | A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques |
| Q28950443 | A human antibody against Zika virus crosslinks the E protein to prevent infection |
| Q33825684 | A human inferred germline antibody binds to an immunodominant epitope and neutralizes Zika virus |
| Q84957921 | A new class of broadly neutralizing antibodies that target the glycan loop of Zika virus envelope protein |
| Q38157419 | A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses |
| Q93065042 | A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection |
| Q41689803 | A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage |
| Q28119745 | ATG16L1 governs placental infection risk and preterm birth in mice and women |
| Q56337689 | Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge |
| Q38156667 | Advances in Developing Therapies to Combat Zika Virus: Current Knowledge and Future Perspectives |
| Q27980653 | Advances in Zika Virus Research: Stem Cell Models, Challenges, and Opportunities |
| Q55084443 | Advances in the research and development of therapeutic antibodies against the Zika virus. |
| Q51336416 | Adverse outcomes of pregnancy-associated Zika virus infection. |
| Q63246516 | An anti-Gn glycoprotein antibody from a convalescent patient potently inhibits the infection of severe fever with thrombocytopenia syndrome virus |
| Q89548894 | Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization |
| Q58588679 | Animal Models of Zika Virus Infection during Pregnancy |
| Q30238657 | Animal Models of Zika Virus Infection, Pathogenesis, and Immunity |
| Q63246196 | Antibodies Elicited by an NS1-Based Vaccine Protect Mice against Zika Virus |
| Q100736905 | Antibodies targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during pregnancy |
| Q51336586 | Antibody-Dependent Enhancement and Zika: Real Threat or Phantom Menace? |
| Q61053646 | CD4+ T cells promote humoral immunity and viral control during Zika virus infection |
| Q59359646 | CD8 T Cell Responses to an Immunodominant Epitope within the Nonstructural Protein NS1 Provide Wide Immunoprotection against Bluetongue Virus in IFNAR Mice |
| Q47552139 | Cellular and Humoral Immunity Protect against Vaginal Zika Virus Infection in Mice |
| Q98205356 | Chemical proteomics tracks virus entry and uncovers NCAM1 as Zika virus receptor |
| Q54979433 | Cleavage-Independent HIV-1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies. |
| Q60031667 | Clinical Trials and Administration of Zika Virus Vaccine in Pregnant Women: Lessons (that Should Have Been) Learned from Excluding Immunization with the Ebola Vaccine during Pregnancy and Lactation |
| Q60031649 | Comprehensive evaluation of differential serodiagnosis between Zika and dengue viral infection |
| Q48106134 | Congenital Zika virus infection as a silent pathology with loss of neurogenic output in the fetal brain |
| Q64979406 | Convalescent patient-derived monoclonal antibodies targeting different epitopes of E protein confer protection against Zika virus in a neonatal mouse model. |
| Q47549528 | Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses |
| Q40047603 | Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections |
| Q94561515 | Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections |
| Q55024075 | Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation. |
| Q30145584 | De Novo Generation and Characterization of New Zika Virus Isolate Using Sequence Data from a Microcephaly Case |
| Q91711499 | Defeat Dengue and Zika Viruses With a One-Two Punch of Vaccine and Vector Blockade |
| Q33798068 | Delineating antibody recognition against Zika virus during natural infection |
| Q61795509 | Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice |
| Q66679191 | Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization |
| Q99726129 | Dengue and Zika Viruses: Epidemiological History, Potential Therapies, and Promising Vaccines |
| Q47558158 | Development of Antibody Therapeutics against Flaviviruses |
| Q64247461 | Development of Neutralizing Antibodies against Zika Virus Based on Its Envelope Protein Structure |
| Q38156855 | Development of Virus like Particle Vaccine and Reporter Assay for Zika Virus |
| Q56000964 | Development of a novel peptide aptamer-based immunoassay to detect Zika virus in serum and urine |
| Q50207356 | Development of vaccines against Zika virus |
| Q38156681 | Differential Neurovirulence of African and Asian Genotype Zika Virus Isolates in Outbred Immunocompetent Mice |
| Q63739941 | Differential human antibody repertoires following Zika infection and the implications for serodiagnostics and disease outcome |
| Q56342279 | Disruption of glial cell development by Zika virus contributes to severe microcephalic newborn mice |
| Q47315490 | Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. |
| Q47570091 | Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic |
| Q94523117 | Evaluating Zika Virus Pathogenesis in Immunocompromised Mice |
| Q45324156 | Experimental Zika Virus Infection of Neotropical Primates |
| Q92446647 | Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies |
| Q51335899 | Fetal Neuropathology in Zika Virus-Infected Pregnant Female Rhesus Monkeys. |
| Q54558643 | Fetal demise and failed antibody therapy during Zika virus infection of pregnant macaques. |
| Q63246157 | Genetic and biochemical characterizations of Zika virus NS2A protein |
| Q90190740 | High specificity and sensitivity of Zika EDIII-based ELISA diagnosis highlighted by a large human reference panel |
| Q91566784 | Homologous prime-boost with Zika virus envelope protein and poly (I:C) induces robust specific humoral and cellular immune responses |
| Q56337984 | Host-Directed Antivirals: A Realistic Alternative to Fight Zika Virus |
| Q91675204 | Human Monoclonal Antibodies Potently Neutralize Zika Virus and Select for Escape Mutations on the Lateral Ridge of the Envelope Protein |
| Q66679208 | Human Polyclonal Antibodies Prevent Lethal Zika Virus Infection in Mice |
| Q61053644 | Human Polyclonal Antibodies Produced from Transchromosomal Bovine Provides Prophylactic and Therapeutic Protections Against Zika Virus Infection in KO Syrian Hamsters |
| Q38157432 | Human Zika infection induces a reduction of IFN-γ producing CD4 T-cells and a parallel expansion of effector Vδ2 T-cells |
| Q58569620 | Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model |
| Q41929032 | Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection |
| Q63248442 | Human antibody response to Zika targets type-specific quaternary structure epitopes |
| Q47558315 | Humoral Immune Responses Against Zika Virus Infection and the Importance of Preexisting Flavivirus Immunity |
| Q29994510 | Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology |
| Q61795459 | Identification of small molecule inhibitors targeting the Zika virus envelope protein |
| Q38158274 | Immune Cell Dynamics in Rhesus Macaques Infected with a Brazilian Strain of Zika Virus |
| Q47551925 | Immune Response to Dengue and Zika |
| Q94948311 | Immune-profiling of ZIKV-infected patients identifies a distinct function of plasmacytoid dendritic cells for immune cross-regulation |
| Q48514697 | Immunization with phage virus-like particles displaying Zika virus potential B-cell epitopes neutralizes Zika virus infection of monkey kidney cells. |
| Q40037937 | Immunization with truncated envelope protein of Zika virus induces protective immune response in mice |
| Q97561560 | Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro |
| Q38158070 | Impact of Zika virus for infertility specialists: current literature, guidelines, and resources |
| Q62485447 | Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika |
| Q92024402 | Impacts of Zika emergence in Latin America on endemic dengue transmission |
| Q63248475 | In Vivo Delivery of a DNA-Encoded Monoclonal Antibody Protects Non-human Primates against Zika Virus |
| Q96128502 | In vivo imaging of Zika virus reveals dynamics of viral invasion in immune-sheltered tissues and vertical propagation during pregnancy |
| Q66680070 | In-depth characterization of congenital Zika syndrome in immunocompetent mice: Antibody-dependent enhancement and an antiviral peptide therapy |
| Q56000963 | Incorporation of NS1 and prM/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E protein |
| Q40052346 | Infection: Zika virus: end of transmission? |
| Q98196926 | Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics |
| Q47684836 | Integrating high-throughput screening and sequencing for monoclonal antibody discovery and engineering. |
| Q97646317 | Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection |
| Q66679510 | Large-scale analysis of B-cell epitopes of envelope: Implications for Zika vaccine and immunotherapeutic development |
| Q38158222 | Lineage-dependent differences in the disease progression of Zika virus infection in type-I interferon receptor knockout (A129) mice |
| Q92449663 | Longitudinal analysis of the antibody repertoire of a Zika virus-infected patient revealed dynamic changes in antibody response |
| Q28223043 | Mapping and Role of the CD8+ T Cell Response During Primary Zika Virus Infection in Mice |
| Q38692329 | Maternal Antiviral Immunoglobulin Accumulates in Neural Tissue of Neonates To Prevent HSV Neurological Disease. |
| Q66680679 | Maternal immunization confers protection against neonatal herpes simplex mortality and behavioral morbidity |
| Q89965788 | Maternal-Fetal Interplay in Zika Virus Infection and Adverse Perinatal Outcomes |
| Q29451356 | Maternal-Fetal Transmission of Zika Virus: Routes and Signals for Infection |
| Q47548888 | Maternal-fetal transmission of the zika virus: An intriguing interplay |
| Q40049416 | Modified mRNA Vaccines Protect against Zika Virus Infection |
| Q54217627 | Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. |
| Q38157121 | Monoclonal antibodies against Zika virus: Therapeutics and their implications for vaccine design |
| Q41919737 | Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. |
| Q41924121 | Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques. |
| Q47558388 | Ontogeny of the B- and T-cell response in a primary Zika virus infection of a dengue-naïve individual during the 2016 outbreak in Miami, FL. |
| Q50046146 | Ophthalmologic Manifestations Associated With Zika Virus Infection |
| Q29994557 | Overview on the Current Status of Zika Virus Pathogenesis and Animal Related Research |
| Q47263584 | Passive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge |
| Q47548101 | Passive immunotherapy of viral infections: 'super-antibodies' enter the fray |
| Q89519312 | Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor |
| Q66679798 | Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes |
| Q61053973 | Pre-Existing Dengue Immunity Drives a DENV-Biased Plasmablast Response in ZIKV-Infected Patient |
| Q45324741 | Preconceptual Zika virus asymptomatic infection protects against secondary prenatal infection. |
| Q48504993 | Pregnancy and infection: using disease pathogenesis to inform vaccine strategy |
| Q47728707 | Preventing neonatal herpes infections through maternal immunization |
| Q30235275 | Prevention and Control Strategies to Counter ZIKA Epidemic |
| Q33715238 | Preventive and therapeutic challenges in combating Zika virus infection: are we getting any closer? |
| Q40043685 | Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design |
| Q30235612 | Prospects for a Zika Virus Vaccine |
| Q99731978 | Protective and enhancing interactions among dengue viruses 1-4 and Zika virus |
| Q60045509 | Protein Microarray Analysis of the Specificity and Cross-Reactivity of Influenza Virus Hemagglutinin-Specific Antibodies |
| Q43039888 | RNA-dependent RNA polymerase: Addressing Zika outbreak by a phylogeny-based drug target study |
| Q54215484 | Rational Engineering and Characterization of an mAb that Neutralizes Zika Virus by Targeting a Mutationally Constrained Quaternary Epitope. |
| Q38158407 | Recent advances in understanding the adaptive immune response to Zika virus and the effect of previous flavivirus exposure |
| Q51782806 | Recombinant Zika virus envelope protein elicited protective immunity against Zika virus in immunocompetent mice. |
| Q91928841 | Recombinant lipidated Zika virus envelope protein domain III elicits durable neutralizing antibody responses against Zika virus in mice |
| Q30145646 | Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico |
| Q92622870 | Risk of Zika microcephaly correlates with features of maternal antibodies |
| Q90148649 | Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies |
| Q90205634 | Serologic Tools and Strategies to Support Intervention Trials to Combat Zika Virus Infection and Disease |
| Q47558373 | Small Molecules and Antibodies for Zika Therapy |
| Q47558337 | Small-Animal Models of Zika Virus |
| Q33888270 | Solution conformations of Zika NS2B-NS3pro and its inhibition by natural products from edible plants |
| Q95603593 | Spondweni virus causes fetal harm in Ifnar1 mice and is transmitted by Aedes aegypti mosquitoes |
| Q93162327 | Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody |
| Q61053963 | Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope |
| Q28804225 | The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis |
| Q59353569 | The Extended Impact of Human Immunodeficiency Virus/AIDS Research |
| Q29051492 | The Race To Find Antivirals for Zika Virus |
| Q47229433 | The Zika virus envelope protein glycan loop regulates virion antigenicity |
| Q59069221 | The emergence of Zika virus and its new clinical syndromes |
| Q51336389 | The immunology of Zika Virus. |
| Q62485478 | The potential contribution of impaired brain glucose metabolism to congenital Zika syndrome |
| Q93078517 | Therapeutic Advances Against ZIKV: A Quick Response, a Long Way to Go |
| Q55084408 | Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. |
| Q58664017 | Therapeutic treatment of Zika virus infection using a brain-penetrating antiviral peptide |
| Q61795505 | Transfusion-Transmitted Zika Virus Infection in Pregnant Mice Leads to Broad Tissue Tropism With Severe Placental Damage and Fetal Demise |
| Q43046904 | Understanding the Pathogenesis of Zika Virus Infection Using Animal Models. |
| Q47558403 | Using immunocompromised mice to identify mechanisms of Zika virus transmission and pathogenesis. |
| Q29571224 | Vaccination strategies against Zika virus |
| Q38157833 | Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease |
| Q90228470 | Virus-Like Particle Systems for Vaccine Development against Viruses in the Flaviviridae Family |
| Q90231838 | Vδ2 T-Cells Kill ZIKV-Infected Cells by NKG2D-Mediated Cytotoxicity |
| Q38157725 | Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Challenges of a Dengue Vaccine |
| Q56337605 | Why is congenital Zika syndrome asymmetrically distributed among human populations? |
| Q91730082 | Zika Vaccine Development: Current Status |
| Q61053650 | Zika Virus Dependence on Host Hsp70 Provides a Protective Strategy against Infection and Disease |
| Q55476040 | Zika Virus Envelope Protein induces G2/M Cell Cycle Arrest and Apoptosis via an Intrinsic Cell Death Signaling Pathway in Neuroendocrine PC12 Cells. |
| Q43046916 | Zika Virus Infects Intermediate Progenitor Cells and Post-mitotic Committed Neurons in Human Fetal Brain Tissues |
| Q58564603 | Zika Virus Liquid Biopsy: A Dendritic Ru(bpy)-Polymer-Amplified ECL Diagnosis Strategy Using a Drop of Blood |
| Q90630667 | Zika Virus NS3 Mimics a Cellular 14-3-3-Binding Motif to Antagonize RIG-I- and MDA5-Mediated Innate Immunity |
| Q28733400 | Zika Virus Pathogenesis and Tissue Tropism |
| Q29587262 | Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys |
| Q47558310 | Zika Virus Structure, Maturation, and Receptors |
| Q32183208 | Zika Virus: Recent Advances towards the Development of Vaccines and Therapeutics |
| Q40037723 | Zika Virus: What Have We Learnt Since the Start of the Recent Epidemic? |
| Q30402859 | Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network |
| Q55084405 | Zika vaccines and therapeutics: landscape analysis and challenges ahead. |
| Q38156674 | Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors. |
| Q40037821 | Zika virus has oncolytic activity against glioblastoma stem cells |
| Q41918368 | Zika virus infection confers protection against West Nile virus challenge in mice |
| Q50020968 | Zika virus outbreak: a review of neurological complications, diagnosis, and treatment options. |
| Q33827467 | Zika virus tropism and interactions in myelinating neural cell cultures: CNS cells and myelin are preferentially affected |
| Q54558329 | Zika virus vaccines: immune response, current status, and future challenges. |
| Q47547461 | Zika virus-related neurotropic flaviviruses infect human placental explants and cause fetal demise in mice |
| Q60031620 | pH Dependence of Zika Membrane Fusion Kinetics Reveals an Off-Pathway State |
Search more.